Clinical Report: Urethra-Sparing SBRT Advances in Prostate Cancer Treatment

Overview

Urethra-sparing stereotactic body radiotherapy (US-SBRT) for localized prostate cancer shows promising reductions in genitourinary toxicity by optimizing radiation doses to the urethra. Two main approaches, urethra-steering and urethra dose-reduction, have been implemented with acceptable acute and late toxicity profiles and no grade 3 toxicities reported in reviewed trials.

Background

Radiation therapy is a cornerstone treatment for localized prostate cancer, with recent technological advances such as IMRT and IGRT improving toxicity profiles. Hypofractionation, including extreme hypofractionated SBRT, has become standard due to favorable radiobiology of prostate cancer. However, genitourinary toxicity remains a concern, with emerging evidence identifying the urethra as a critical organ at risk influencing long-term toxicity. Urethra-sparing techniques aim to reduce radiation dose to the urethra to mitigate these toxicities.

Data Highlights

Key Findings

• Urethra-sparing SBRT techniques include urethra-steering and urethra dose-reduction approaches to limit radiation dose to the urethra.
• In urethra-steering trials, acute grade 2 genitourinary toxicity ranged from 15% to 52%, mostly dysuria and urinary frequency, with no grade 3 toxicities reported.
• Late grade 2 genitourinary toxicity was generally low (12.1% to 14%) and consisted mainly of urinary frequency and urgency.
• Dose constraints to the urethra varied, with some protocols limiting maximal urethral dose to 42 Gy, though actual delivered doses sometimes exceeded this.
• Shortening overall treatment time from once-weekly to semi-weekly increased acute grade 2 GU toxicity significantly.
• Quality of life assessments showed transient toxicity flare post-SBRT with return to baseline by 3 months.

Clinical Implications

Incorporating urethra-sparing techniques in prostate SBRT can reduce genitourinary toxicity without compromising oncological outcomes. Careful planning to limit urethral dose and consideration of treatment scheduling may optimize patient tolerance. These approaches support safer hypofractionated regimens for localized prostate cancer.

Conclusion

Urethra-sparing SBRT represents a promising advancement in minimizing genitourinary toxicity in prostate cancer radiotherapy. Continued refinement of dose constraints and treatment protocols is warranted to further improve patient outcomes.

References

1. McDonald et al. 2020 -- Urethra-Sparing SBRT Pilot Study
2. Hypo-FLAME Trial 2021 -- Dose Escalation with Urethra Constraints
3. HYPOFLAME 2.0 Trial 2022 -- Treatment Time and Toxicity
4. Cloitre et al. 2023 -- CyberKnife Dose Escalation with Urethra Sparing